Oral vs. Injectable GLP-1: Which Weight Loss Medication Is Right for You?

If you're considering a GLP-1 medication for weight management, one of the first decisions you'll face is how you want to take it. The landscape has shifted: once limited to weekly injections, GLP-1 therapy is now available in daily oral forms as well.

This guide compares the two approaches -- injectable and oral -- so you can have a more informed conversation with your provider.

The Options at a Glance

There are currently two FDA-approved oral GLP-1 options for weight management, alongside the established injectable:

Injectable semaglutide (Wegovy) -- a once-weekly subcutaneous injection that has the longest track record in weight-management trials.

Oral semaglutide 25 mg (Wegovy tablets) -- the same semaglutide molecule delivered as a daily pill, approved in December 2025. This is a peptide formulated with an absorption enhancer (SNAC) to survive stomach acid.

Foundayo (orforglipron) -- a once-daily non-peptide oral GLP-1 receptor agonist from Eli Lilly. Because it is a small molecule rather than a peptide, it does not require special formulation, refrigeration, or food-timing restrictions.

How They Compare: Efficacy

Direct head-to-head trials between these three options are limited. What we have are separate clinical programs:

Branded injectable semaglutide (Wegovy): In the STEP trials, adults receiving semaglutide 2.4 mg alongside diet and exercise lost an average of about 15% of body weight over 68 weeks. The SELECT trial also showed a 20% reduction in major adverse cardiovascular events.

Oral semaglutide 25 mg: Clinical data supports the 25 mg dose as the weight-management formulation. Novo Nordisk's official pricing is $299/month for the 9 mg and 25 mg strengths.

Foundayo (orforglipron): In the ATTAIN-1 trial, adults without diabetes taking orforglipron alongside diet and exercise achieved average weight loss of 7.4% at 5.5 mg, 8.3% at 9 mg, and 11.1% at 17.2 mg over 72 weeks, compared to 2.1% for placebo.

These numbers come from different trial populations and designs. Comparing them directly requires caution, and your individual results may differ from trial averages.

Convenience and Lifestyle Factors

This is often where the decision becomes practical rather than clinical:

Injection considerations: Once-weekly dosing means fewer daily decisions. The injection is subcutaneous (small needle, typically in the abdomen or thigh) and most patients describe it as nearly painless. However, it requires refrigeration and a comfort level with self-injection.

Oral semaglutide considerations: Daily pill, but with specific requirements -- it must be taken on an empty stomach with no more than 4 ounces of water, and you need to wait at least 30 minutes before eating or taking other medications. This timing constraint can be inconvenient for some patients.

Foundayo considerations: Daily pill with no food-timing restrictions. It can be taken any time of day, with or without food, and does not require refrigeration. For patients who want the simplicity of a pill without absorption-related constraints, this is a meaningful advantage.

Side Effect Profiles

All GLP-1 receptor agonists share a similar gastrointestinal side-effect profile. The most common are nausea, vomiting, diarrhea, and constipation. These tend to be most pronounced during dose escalation and typically improve over time.

All carry boxed-warning considerations related to thyroid C-cell tumors observed in rodent studies. They should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Foundayo has an additional consideration: it may reduce the effectiveness of oral contraceptives. Patients using hormonal birth control should discuss alternative or backup contraception with their provider.

Cost Considerations

Pricing for GLP-1 medications varies based on insurance coverage, manufacturer programs, and pharmacy:

• Foundayo is priced starting at $149/month through Varus.
• Oral semaglutide (Wegovy tablets) is priced starting at $299/month for the 25 mg dose through Varus.
• Injectable semaglutide (Wegovy) pricing depends on manufacturer-direct or retail-pharmacy fulfillment pathways. Varus can discuss eligibility through a provider consultation.

Insurance coverage for weight-management medications has improved but remains inconsistent. Your provider can help navigate coverage options.

Who Is a Candidate?

GLP-1 medications are generally indicated for adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related medical condition such as type 2 diabetes, hypertension, or high cholesterol.

Foundayo is specifically indicated along with a reduced-calorie diet and increased physical activity. It is not for cosmetic weight loss.

A licensed provider evaluates your full medical history, current medications, and treatment goals before determining whether any GLP-1 therapy is appropriate and which option best fits your situation.

Making the Decision

There is no universally "best" GLP-1 medication. The right choice depends on:

• Needle comfort: If self-injection is a barrier, oral options remove it entirely.
• Lifestyle fit: Foundayo's no-restrictions dosing may suit patients with unpredictable schedules. Oral semaglutide's fasting requirement may not.
• Efficacy goals: Injectable semaglutide has the strongest published weight-loss data, though individual responses vary.
• Cost: Significant price differences exist between options.
• Clinical profile: Your provider will consider your full medical history, including contraindications and medication interactions.

The best starting point is a conversation with a licensed clinician who can evaluate your specific situation and recommend the most appropriate path.